Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.
The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.
The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.
A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.
The firm's shares rose past 7% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.